Multiple sclerosis, cannabinoids, and cognition

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 20, Issue 1, 2008, Pages 36-51

  Papathanasopoulos, Panagiotis ^a   Messinis, Lambros ^a   Lyros, Epameinondas ^a   Kastellakis, Andreas ^b   Panagis, George ^b  

^a UNIVERSITY OF PATRAS   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; AZATHIOPRINE; BETA INTERFERON; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID DERIVATIVE; CANNABIS; CORTICOSTEROID DERIVATIVE; DRONABINOL; ENDOCANNABINOID; INTERFERON BETA SERINE; METHYLPREDNISOLONE; NABILONE; NOLADIN ETHER; PLACEBO; PLANT EXTRACT; TETRAHYDROCANNABINOL; VIRODHAMINE;

ASPIRATION PNEUMONIA; BRAIN FUNCTION; CLINICAL FEATURE; COGNITION; COGNITIVE DEFECT; DIZZINESS; DOSE RESPONSE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG EXPOSURE; DRUG INHIBITION; DRUG SAFETY; DRUG TOLERABILITY; EVOKED AUDITORY RESPONSE; EXCITOTOXICITY; FALLING; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GASTROENTERITIS; GILLES DE LA TOURETTE SYNDROME; HIPPOCAMPUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; INTOXICATION; LEARNING; LONG TERM EXPOSURE; LOW DRUG DOSE; MEMORY; MULTIPLE SCLEROSIS; NERVE CELL PLASTICITY; NERVOUS SYSTEM; NEUROLOGIC DISEASE; NEUROPROTECTION; NEUROPSYCHIATRY; NEUROPSYCHOLOGICAL TEST; NEUROPSYCHOLOGY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEIZURE; SIDE EFFECT; SOMNOLENCE; SPASTICITY; STRUCTURAL EQUATION MODELING; SYMPTOMATOLOGY; UNSPECIFIED SIDE EFFECT; WITHDRAWAL SYNDROME; WORKING MEMORY; XEROSTOMIA;

EID: 39749112424     PISSN: 08950172     EISSN: None     Source Type: Journal    
DOI: 10.1176/jnp.2008.20.1.36     Document Type: Review

References (126)

1. Ben Amar M: Cannabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol 2006; 105:1-25
2. Baker D, Pryce G, Giovannoni G, et al: The therapeutic potential of cannabis. Lancet Neurology 2003; 2:291-298
3. Iversen L: Cannabis and the brain. Brain 2003; 126:1252-1270
4. Pryce G, Baker D: Emerging properties of cannabinoid medicines in management of multiple sclerosis. Trends Neurosci 2005; 28:272-276
5. Clark AJ, Ware MA, Yazer E, et al: Patterns of cannabis use among patients with multiple sclerosis. Neurology 2004; 62:2098-2100
6. Brady CM, DasGupta R, Dalton C, et al: An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler 2004; 10:425-433
7. Fox P, Bain PG, Glickman S, et al: The effect of cannabis on tremor in patients with multiple sclerosis. Neurology 2004; 62:1105-1109
8. Killestein J, Hoogervorst EL, Reif M, et al: Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 2002; 58:1404-1407
9. Rog DJ, Nurmiko T, Friede T, et al: Randomized controlled trial of cannabis based medicine in central neuropathic pain due to multiple sclerosis. Neurology 2005; 65:812-819
10. Russo EB: Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 2003; 60:729-730
11. Svendsen KB, Jensen TS, Bach FW: Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. Bri Med J 2004; 329:253
12. Vaney C, Heinzel-Gutenbrunner M, Jobin P, et al: Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler 2004; 10:417-424
13. Wade DT, Makela P, Robson P, et al: Do cannabis based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004; 10:434-441
14. Wade DT, Makela PM, House H, et al: Long-term use of cannabis-based medicine in the treatment of spasticity and other symptoms of multiple sclerosis. Mult Scler 2006; 12:639-645
15. Zajicek J, Fox P, Sanders H, et al: Cannabinoids for the treatment of other symptoms related to multiple sclerosis (CAMS study): multicentre, randomized, placebo-controlled trial. Lancet 2003; 362:1517-1526
16. Zajicek J, Fox P, Sanders HP, et al: Cannabinoids in multiple sclerosis (CAMS study): safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 2005; 76:1664-1669
17. Pertwee RG: Cannabinoids and multiple sclerosis. Pharmacol Ther 2002; 95:165-174
18. Jackson SJ, Diemel LT, Pryce G, et al: Cannabinoids and neuroprotection in CNS inflammatory disease. J Neurol Sci 2005; 233:21-25
19. Smith PF: The safety of cannabinoids for the treatment of multiple sclerosis. Expert Opin Drug Saf 2005; 4:443-456
20. Bowling A: Cannabinoids in MS: are we any closer to knowing how best to use them? Mult Scler 2006; 12:523-525
21. Russo EB, Guy GW: A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 2006; 66:234-246
22. Grant I, Gonzalez R, Carey CL, et al: Non-acute (residual) neurocognitive effects of cannabis use: a meta-analytic study. J Int Neuropsychol Soc 2003; 9:679-689
23. Messinis L, Kyprianidou A, Malefaki S, et al: Neuropsychological deficits in long-term frequent cannabis users. Neurology 2006; 66:737-739
24. Solowij N, Michie PD: Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia? J Psychiatry Neurosci 2007; 32:30-52
25. Bovasso GB: Cannabis abuse as a risk factor for depressive symptoms. Am J Psychiatry 2001; 158:2033-2037
26. Johns A: Psychiatric effects of cannabis. Br J Psychiatry 2001; 178:116-122
27. Nunez LA, Gurpegui M: Cannabis-induced psychosis: a cross-sectional comparison with acute schizophrenia. Acta Psychiatry Scand 2002; 10:173-178
28. Iversen L: Long-term effects of exposure to cannabis. Curr Opin Pharmacol 2005; 5:69-72
29. Budney AJ, Hughes JR, Moore BA, et al: Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry 2004; 161:1967-1977
30. Budney AJ, Hughes JR: The cannabis withdrawal syndrome. Curr Opin Psychiatry 2006; 19:233-238
31. Smith NT: A review of the published literature into cannabis withdrawal symptoms in human users. Addiction 2002; 97:621-632
32. Crowley TJ, Macdonald MJ, Whitmore EA, et al: Cannabis dependence, withdrawal, and reinforcing effects among adolescents with conduct symptoms and substance use disorders. Drug Alcohol Depend 1998; 50:27-37
33. Roffman RA, Klepsch R, Wertz JS, et al: Predictors of attrition from an outpatient marijuana-dependence counselling program. Addict Behav 2003; 18:553-566
34. Soellner R: Dependence on cannabis: an everlasting issue. Subst Use Misuse 2005; 40:857-867
35. Matsuda LA, Lolait SJ, Brownstein MJ, et al: Structure of a cannabinoid receptor and functional expression of the cloned CDNA. Nature 1990; 346:561-564
36. Munro S, Thomas KL, Abu-Shaar M: Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365:61-65
37. Begg M, Pacher P, Batkai S, et al: Evidence for novel cannabinoid receptors. Pharmacol Ther 2005; 106:133-145
38. Mechoulam R, Ben-Shabat S, Hanus L, et al: Identification of an endogenous 2-monoglyceride, present in canine gut that binds to cannabinoid receptors. Biochem Pharmacol 1995; 50:83-90
39. Mechoulam R, Parker LA, Gallily R: Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol 2002; 42:11S-19S.
40. Schlicker E, Kathmann M: Modulation of neurotransmitter release via presynaptic cannabinoid receptors. Trends in Pharmacol Sci 2001; 22:565-572
41. Gong JP, Onaivi ES, Ishiguro H, et al: Cannabinoid CB2 receptors: immunohistochemical localization in the rat brain. Brain Res 2006; 107:110-123
42. Piomelli D: The molecular logic of endocannabinoid signaling. Nat Rev Neurosci 2003; 4:873-884
43. Pertwee RG: The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J 2005; 7:E625-E654
44. Bahr BA, Karanian DA, Makanji SS, et al: Targeting the endocannabinoid system in treating brain disorders. Expert Opin Investig Drugs 2006; 15:351-365
45. 9- tetrahydrocannabinol on forebrain ischemia in rat. Brain Res 2000; 857:183-187
46. Nagayama T, Sinor AD, Simon RP, et al: Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci 1999; 19:2987-2995
47. Panikashvili D, Simeonidou C, Ben-Shabat S, et al: An endogenous cannabinoid (2-arachidonylglycerol) is neuroprotective after brain injury. Nature 2001; 413:527-531
48. Dirnagl U, Costantino L, Moskowitz P: Pathobiology of ischemic stroke: an integrated view. Trends Neurosci 1999; 22:391-397
49. Nicotera P, Leist M, Manzo L: Neuronal cell death: demise with different shapes. Trends Pharmacol Sci 1999; 20:46-51
50. Marsicano G, Goodenough S, Monory K, et al: CB1 cannabinoid receptors and on-demand defence against excitoxicity. Science 2003; 302:84-88
51. Shen M, Piser TM, Seybold US, et al: Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J Neurosci 1996; 16:4322-4334
52. Baker D, Pryce G, Croxford JL, et al: Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 2001; 15:300-302
53. Witting A, Chen L, Cudaback E, et al: Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection. Proc Natl Acad Sci USA 2006; 103:6362-6367
54. Gorelick DA, Heishman SJ: Methods for clinical research involving cannabis administration. Methods Molec Med 2006; 123:235-253
55. Pope HG Jr, Gruber AJ, Hudson JI, et al: Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry 2001; 58:909-915
56. Bolla KI, Brown K, Eldreth D, et al: Dose-related neurocognitive effects of marijuana use. Neurology 2002; 59:1337-1343
57. Solowij N, Stephens RS, Roffman RA, et al: Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 2002; 287:1123-1131
58. Fletcher JM, Page JB, Francis DJ, et al: Cognitive correlates of long-term cannabis use in Costa Rican men. Arch Gen Psychiatry 1996; 53:1051-1057
59. Ehrenreich H, Rinn T, Kunert HJ, et al: Specific attentional dysfunction in adults following early start of cannabis use. Psychopharmacology 1999; 142:295-301
60. Pope HG Jr, Gruber AJ, Hudson JI, et al: Early-onset cannabis use and cognitive deficits: what is the nature of the association? Drug Alcohol Depend 2003; 69:303-310
61. Huestegge L, Radach R, Kunert HJ, et al: Visual search in long-term cannabis users with early age of onset. Prog Brain Res 2002; 140:377-394
62. Wilson WH, Mathew RJ, Turkington TG, et al: Brain morphological changes and early marijuana use: a magnetic resonance and positron emission tomography study. J Addict Dis 2000; 19:1-22
63. Macleod J, Oakes R, Copello A, et al: Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies. Lancet 2004; 363:1579-1588
64. Tzilos GK, Cintron CB, Wood JB, et al: Lack of hippocampal volume change in long-term heavy cannabis users. Am J Addict 2005; 14:64-72
65. Solowij N: Cannabis and Cognitive Functioning. Cambridge, UK, Cambridge University Press, 1998
66. Struve FA, Patrick G, Straumanis JJ, et al: Possible EEG sequelae of very long duration marihuana use: pilot findings from topographic quantitative EEG analyses of subjects with 15 to 24 years of cumulative daily exposure to THC. Clin Electroencephalogr 1998; 29:31-36
67. Block RI, O'Leary DS, Ehrhardt JC, et al: Effects of frequent marijuana use on brain tissue volume and composition. Neuroreport 2000; 11:491-496
68. Matochik JA, London EL, Eldreth DA, et al: Altered brain tissue composition in heavy marijuana users. Drug Alcohol Depend 2005; 77:23-30
69. Block RI, O'Leary DS, Hichwa RD, et al: Effects of frequent marijuana use on memory-related regional cerebral blood flow. Pharmacol Biochem Behav 2002; 72:237-250
70. Eldreth DA, Matochik JA, Cadet JL, et al: Abnormal brain activity in prefrontal brain regions in abstinent marijuana users. Neuroimage 2004; 23:914-920
71. Bolla KI, Eldreth DA, Matochik JA, et al: Neural substrates of faulty decision-making in abstinent marijuana users. Neuroimage 2005; 26:480-492
72. Kanayama G, Rogowska J, Pope HG, et al: Spatial working memory in heavy cannabis users: a functional magnetic resonance imaging study. Psychopharmacology 2004; 176:239-247
73. Jacobsen LK, Mencl WE, Westerveld M, et al: Impact of cannabis use on brain function in adolescents. Ann N Y Acad Sci 2004; 1021:384-390
74. Jager G, Kahn RS, Van Den Brink W, et al: Long-term effects of frequent cannabis use on working memory and attention: an fMRI study. Psychopharmacology 2006; 185:358-368
75. Respondek C, Solowij N, Ward P: Functional magnetic resonance imaging indices of memory function in long-term cannabis users. World J Biol Psychiatry 2004; 5(S1):S131
76. Compston A, Coles A: Multiple sclerosis. Lancet 2002; 359:1221-1231
77. Calabrese P: Neuropsychology of multiple sclerosis: an overview. J Neurology 2006; 253:10-15
78. Rao SM, Leo GJ, Ellington L, et al: Cognitive dysfunction in multiple sclerosis: impact on employment and social functioning. Neurology 1991; 41:692-696
79. Zakzanis KK: Distinct neurocognitive profiles in multiple sclerosis subtypes. Arch Clin Neuropsychol 2000; 15:115-136
80. Denney DR, Sworowski LA, Lynch SG: Cognitive impairment in three subtypes of multiple sclerosis. Arch Clin Neuropsychol 2005; 20:967-981
81. Nocentini U, Pasqualetti P, Bonavita S, et al: Cognitive dysfunction in patients with relapsing-remitting multiple sclerosis. Mult Scler 2006; 12:77-87
82. Hoffmann S, Tittgemeyer M, Yves von Cramon D: Cognitive impairment in multiple sclerosis. Curr Opin Neurol 2007; 20:275-280
83. Henry JD, Beatty WW: Verbal fluency deficits in multiple sclerosis. Neuropsychologia 2006; 44:1166-1174
84. Olivares T, Nieto A, Sanchez MP, et al: Pattern of neuropsychological impairment in the early phase of relapsing-remitting multiple sclerosis. Mult Scler 2005; 11:191-197
85. Litvan J, Grafman J, Vendrell P, et al: Multiple memory deficits in patients with multiple sclerosis: exploring the working memory system. Arch Neurol 1988; 45:607-610
86. Pelosi L, Geesken JM, Holl M, et al: Working memory impairment in early multiple sclerosis: evidence from an event-related potential study of patients with clinically isolated myelopathy. Brain 1997; 120:2039-2058
87. Achiron A, Barak Y: Cognitive impairment in probable multiple sclerosis. J Neurol Neurosur Psychiatry 2003; 74:443-446
88. Baddeley Á: Working memory. Science 1992; 255:556-559
89. Paulesu E, Frith CD, Frackowiak RSJ: The neural correlates of the verbal component of working memory. Nature 1993; 362:342-344
90. Lazeron RH, Boringa JB, Schouten M, et al: Brain atrophy and lesion load as explaining parameters for cognitive impairment in multiple sclerosis. Mult Scler 2005; 11:524-531
91. Rovaris M, Filippi M, Falautano L, et al: Relation between MR abnormalities and patterns of cognitive impairment in multiple sclerosis. Neurology 1998; 50:1601-1608
92. Zivadinov VR, De Masi D, Nasuelli LM, et al: MRI techniques and cognitive impairment in the early phase of relapsing-remitting multiple sclerosis. Neuroradiology 2001; 43:272-278
93. Audoin B, Ibarrola JP, Ranjeva S, et al: Compensatory cortical activation observed by fMRI during a cognitive task at the earliest stage of MS. Hum Brain Mapp 2003; 20:51-58
94. Staffen WA, Mair H, Zauner A, et al: Cognitive function and fMRI in patients with multiple sclerosis: evidence for compensatory cortical activation during an attention task. Brain 2002; 125:1275-1282
95. Feinstein A: The neuropsychiatry of multiple sclerosis. Can J Psychiatry 2004; 49:157-163
96. Ghaffar O, Feinstein A: The neuropsychiatry of multiple sclerosis: a review of recent developments. Curr Opin Psychiatry 2007; 20:278-285
97. Demaree HA, Gaudino E, DeLuca J: The relationship between depressive symptoms and cognitive dysfunction in multiple sclerosis. Cognit Neuropsychiatry 2003; 8:161-171
98. Feinstein A: Mood disorders in multiple sclerosis and the effects on cognition. J Neurol Sci 2006; 245:63-66
99. Lazeron RH, Rombouts SA, Scheltens PH, et al: An fMRI study of planning-related brain activity in patients with moderately advanced multiple sclerosis. Mult Scler 2004; 10:549-555
100. Au Duong MV, Boulanouar K, Audoin B, et al: Modulation of effective connectivity inside the working memory network in patients at the earliest stage of multiple sclerosis. Neuroimage 2005; 24:533-538
101. Mesulam M: Brain, mind, and the evolution of connectivity. Brain Cogn 2000; 42:4-6
102. Langdon DW, Thompson AJ, Johnson KP, et al: The psychological effects of cannabis in MS: impact on cognition, pain, mood and fatigue (abstract). Mult Scler ECTRIMS 2003; 9:S27
103. Karst M, Salim K, Burstein S, et al: Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain. JAMA 2003; 290:1757-1762
104. Wissel J, Haydn T, Muller J, et al: Low dose treatment with the synthetic cannabinoid nabilone significantly reduces spasticity-related pain: a double blind placebo-controlled cross-over trial. J Neurol 2006; 253:1337-1341
105. Kurzthaler I, Bodner T, Kemmler G, et al: The effect of nabilone on neuropsychological functions related to driving ability: an extended case series. Hum Psychopharmacol 2005; 20:291-293
106. Muller-Vahl KR, Prevedel H, Theloe K, et al: Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (delta 9-THC): no influence on neuropsychological performance. Neuropsychopharmacology 2003; 28:384-388
107. Sim-Selley LJ: Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. Crit Rev Neurobiol 2003; 15:91-119
108. Hampson RE, Simeral JD, Kelly EJ, et al: Tolerance to the memory disruptive effects of cannabinoids involves adaptation by hippocampal neurons. Hippocampus 2003; 13:543-556
109. Kelleher LM, Stough C, Sergejew AA, et al: The effects of cannabis on information-processing speed. Addict Behav 2004; 6:1213-1219
110. Hoffman AF, Oz M, Caulder T, et al: Functional tolerance and blockade of long-term depression at synapses in the nucleus accumbens after chronic cannabinoid exposure. J Neurosci 2003; 23:4815-4820
111. Robbe G, Alonso O, Manzoni J: Exogenous and endogenous cannabinoids control synaptic transmission in mice nucleus accumbens. Ann N Y Acad Sci 2003; 1003:212-225
112. Mato S, Robbe D, Puente N, et al: Presynaptic homeostatic plasticity rescues long-term depression after chronic delta 9-tetrahydrocannabinol exposure. J Neurosci 2005; 25:11619-11627
113. Hampson RE, Deadwyler SA: Cannabinoids reveal the necessity of hippocampal neural encoding for short-term memory in rats. J Neurosci 2000; 20:8932-8942
114. Kim D, Thayer SA: Cannabinoids inhibit the formation of new synapses between hippocampal neurons in culture. J Neurosci 2001; 21:RC146
115. D'Intino G, Paradisi M, Fernandez M, et al: Cognitive deficits associated with cholinergic and nerve growth factor down-regulation in experimental allergic encephalomyelitis in rats. Proc Natl Acad Sci USA 2005; 102:3070-3075
116. White DA, Heaton RK, Monsch AU: Neuropsychological studies of asymptomatic human immunodeficiency virus-type-1 infected individuals. The HNRC Group. HIV Neurobehavioral Res Center. J Int Neuropsychol Soc 1995; 1:304-315
117. Ernst T, Chang L, Jovicich J, et al: Abnormal brain activation on functional MRI in cognitively asymptomatic HIV patients. Neurology 2002; 59:1343-1349
118. Cristiani SA, Pukay-Martin ND, Bornstein RA: Marijuana use and cognitive function in HIV-infected people. J Neuropsychiatry Clin Neurosci 2004; 16:330-335
119. Fernandez UD: Treatment of multiple sclerosis. Neurologia 1999; 14(S6):1-12
120. Henze T, Rieckman P, Toyka KV: Symptomatic treatment of multiple sclerosis. Eur Neurol 2006; 56:78-105
121. Kendrick M, Johnson KI: Long-term treatment of multiple sclerosis with interferon-beta may be cost effective. Pharmacoeconomics 2000; 18:45-53
122. Kappos L, Polman CH, Freedman MS, et al: Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67:1242-1249
123. Smith PF: Sativex (GW-1000). Curr Opin Investig Drugs 2004; 5:748-754
124. Wade DT, Robson P, House H, et al: A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003; 17:21-29
125. Mestre L, Correa F, Arevalo-Martin O: Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. J Neurochem 2005; 92:1327-1339
126. Hentges ST, Low MJ, Williams JT: Differential regulation of synaptic inputs by constitutively released endocannabinoids and exogenous cannabinoids. J Neurosci 2005; 25:9746-9751